Pending · due 19 Aug 2028

The FDA approves a novel psychedelic drug product whose labeling and REMS omit any requirement for in-clinic monitoring of the patient during and after dosing.

Resolved on Drugs@FDA (approval letters and labeling) read with REMS@FDA. A novel psychedelic drug product is the first FDA-approved product with a psychedelic or entactogen active ingredient (the class the forecaster illustrates with psilocybin, LSD and MDMA); ketamine and esketamine products and new formulations of approved drugs do not count. TRUE on the approval date of the first such product, approved after the statement date, whose labeling and REMS require no monitoring of the patient by a healthcare provider during or after dosing (no observation period, no certified-setting dosing requirement). FALSE at the deadline if at least one such product has been approved and every one requires in-clinic monitoring during or after dosing. If none is approved in the window, the condition is unmet and the item is void.

Resolution source: Drugs@FDA (approval letters and labeling) with the FDA REMS database (REMS@FDA)

Readings: Split -a: 'will come with monitoring built in' as a denial. 'If the universe has been listening' is an aside, not a condition.; 'monitoring built in' = an FDA-required monitoring element (REMS or labeling), per the REMS section context; resolved on the first qualifying approval.; The auditable-video clause is split off as owen-2343-b.